JenaValve Technology, Inc.

📍 Irvine, United States🗓 Founded 2013👥 152 employees💰 Last funded Jul 2015
Medical Equipment Manufacturing🌐 jenavalve.com
Website LinkedIn
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
2
Frequently asked questions
Who invested in JenaValve Technology, Inc.?
JenaValve Technology, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did JenaValve Technology, Inc. last raise funding?
The most recent investment in JenaValve Technology, Inc. recorded on gritt.io was in July 2015.
When was JenaValve Technology, Inc. founded?
JenaValve Technology, Inc. was founded in 2013.
What industry is JenaValve Technology, Inc. in?
JenaValve Technology, Inc. operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is JenaValve Technology, Inc. based?
JenaValve Technology, Inc. is headquartered in Irvine, United States.